Clinical Trials on Moderate-to-Severe Plaque Psoriasis in Sweden

Total 21 results

AbbVie (prior sponsor, Abbott)

Completed

Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (LOTOS)

Moderate to Severe Plaque Psoriasis

Germany
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Mundipharma Research GmbH & Co KG

Completed

Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Moderate to Severe Idiopathic RLS With Daytime Symptoms

Spain, Sweden, Germany
Kristian Reich, MD
LEO Pharma

Completed

Optimising Outpatient Care in Mild to Moderate Psoriasis (PSO-TOP) (PSO-TOP)

Mild to Moderate Psoriasis

United Kingdom, Germany, France, Spain, Netherlands, Sweden, Italy, Denmark
Biocool AB

Completed

Investigation With BiopH+Psoriasis Medical Bath in Subject With Mild to Moderate Plaque Psoriasis.

Plaque Psoriasis

Sweden
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines. (ULTRA II)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

Germany
AstraZeneca

Not yet recruiting

Phase IIa Study Evaluating AZD7798 in Crohn's Disease (AMALTHEA)

Moderate to Severe Crohn's Disease

United States, Vietnam, Turkey, Malaysia, Taiwan, Spain, Germany, Italy, Chile, Slovakia, Brazil, Japan, Bulgaria, Ukraine, South Africa, Argentina, Australia, Romania, Austria, Mexico, Sweden
AstraZeneca

Completed

Study to Assess the Efficacy and Safety of AZD1981 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (Columbus)

Moderate to Severe COPD

Sweden, Bulgaria, Poland, Denmark, Slovakia
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of the Efficacy of Early Intervention With Secukinumab 300 mg s.c. Compared to Narrow-band UVB in Patients With New-onset Moderate to Severe Plaque Psoriasis (STEPin)

Plaque Psoriasis

Spain, United Kingdom, Estonia, Germany, Bulgaria, Finland, Hungary, Poland, Argentina, Canada, Denmark, Switzerland, Sweden
LEO Pharma

Terminated

Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab (COBRA)

Psoriasis | Plaque Psoriasis | Psoriasis Vulgaris

Belgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
Göteborg University
University of Boras

Recruiting

Talking Mats as Decision Aid for Older People Living With Mild to Moderate Dementia

Mild to Moderate Dementia

Sweden
Abbott

Completed

Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment (BELIEVE)

Chronic Plaque Psoriasis

Belgium, Denmark, France, Germany, Spain, Sweden, Switzerland, Finland, Turkey, Italy, Czech Republic, Austria, Netherlands, United Kingdom, Greece
Novartis Pharmaceuticals

Completed

Plaque Psoriasis Efficacy and Safety With Secukinumab (OPTIMISE)

Plaque Psoriasis

Germany, Belgium, Spain, Croatia, Czechia, Greece, Hungary, Russian Federation, Netherlands, Austria, France, Switzerland, Israel, United Kingdom, Italy, Lithuania, Sweden, Bulgaria, Denmark, Finland, Portugal, Slovakia, Poland, Latvia
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Secukinumab Compared to Etanercept in Subjects With Moderate to Severe, Chronic Plaque-Type Psoriasis (FIXTURE)

Chronic Plaque Psoriasis

Germany, United States, Colombia, Italy, Spain, Belgium, Egypt, Hungary, Australia, Singapore, France, Sweden, Guatemala, Philippines, Korea, Republic of, United Kingdom, Argentina, Poland, Romania, Canada, Iceland, India, Finland
AbbVie

Completed

Chronic Plaque Psoriasis (Ps) Registry

Chronic Plaque Psoriasis

United States, Austria, Canada, Czechia, Denmark, France, Germany, Greece, Ireland, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom
AbbVie

Active, not recruiting

Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE)

Chronic Plaque Psoriasis

Argentina, Australia, Austria, Canada, Colombia, Czechia, France, Germany, Hungary, Ireland, Italy, Japan, Mexico, Netherlands, Poland, Romania, Saudi Arabia, Spain, Switzerland, United Arab Emirates, United Kingdom
Pfizer

Completed

A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis. (ADEQUATE)

Rheumatoid Arthritis | Plaque Psoriasis | Psoriatic Arthritis | Axial Spondyloarthritis

Germany
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
PharmatrophiX Inc.
National Institute on Aging (NIA)

Completed

Study of LM11A-31-BHS in Mild-moderate AD Patients

Mild to Moderate Alzheimer's Disease

Spain, Germany, Austria, Czechia, Sweden

Clinical Trials on Moderate-to-Severe Plaque Psoriasis in Sweden

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations